Popular Trials
Longitudinal Remote Consultation for Postpartum Depression
This study evaluates the impact of a longitudinal remote consultation (LRC) implementation strategy for collaborative care depression treatment among perinatal women. All participating health centers will receive training in collaborative care. Cluster randomization will be used to assign the addition of LRC to select health centers. Differences in implementation success, clinical outcomes, and costs will be compared after a 12 month implementation period and 13-21 month sustainment period.
Procedure
Esophagogastroduodenoscopy (EGD) for Barrett's Esophagus
The NvisionVLE® Dysplasia Detection Pilot Study is a prospective, non-randomized trial for participants who have a prior biopsy-confirmed diagnosis of BE with dysplasia and are scheduled to have an endoscopic evaluation of your esophagus for BE surveillance by a standard procedure called EGD (esophagogastroduodenoscopy) as well as an imaging procedure called VLE (volumetric laser endomicroscopy).
Intraocular Lens
Tecnis Multifocal 1-Piece IOL for Cataract
The objective of this study is to evaluate the uncorrected binocular distance, intermediate, and near visual acuities, and assess patient's spectacle independence and satisfaction in individuals undergoing bilateral cataract extraction that have received two different arms of near add design IOLs of the same diffractive multifocal model.
Cell Therapy
NT-501 ECT Implant for Glaucoma
This trial tests a new eye implant called NT-501 for people with glaucoma. The implant releases medicine directly into the eye to help protect it from damage. It aims to help those who may not respond well to usual treatments. An earlier version of this implant has been used to help manage glaucoma in patients who did not benefit from other treatments.
Popular Filters
Phase 3 Trials
Behavioural Intervention
Office-based vergence/accommodative therapy for Convergence Insufficiency
CITT-ART is a multicenter study (8 locations around the United States) of 324 children ages 9 to \<14 years with symptomatic convergence insufficiency (CI). The purpose of this study is to see if office-based therapy for convergence insufficiency (CI) improves reading ability and attention. CI is an eye-teaming problem where the eyes would like to drift outward when reading or doing close work. When eyes drift out, double vision can happen. To prevent double vision one must use extra effort to keep the eyes from going out. This extra effort can cause symptoms that can interfere with reading and working comfortably at near. These symptoms often include eyestrain, blurred vision, headaches, double vision, and loss of place when reading or performing tasks at near. In a prior study we found that therapy improves these symptoms. In this study we are looking at whether the therapy improves reading and attention
Corneal Inlay
Raindrop Near Vision Inlay for Presbyopia
The objective of this study is to evaluate the safety and effectiveness of the Raindrop Near Vision Inlay implanted in bilateral pseudophakes with presbyopia for improvement of near and intermediate vision.
Apoptosis Inducer
Xevinapant + Radiotherapy for Head and Neck Cancer
This trial tests Xevinapant combined with radiotherapy for high-risk head and neck cancer patients who can't use standard treatment. The drug aims to make cancer cells more sensitive to radiation, improving treatment effectiveness. Xevinapant is a newer drug being tested to enhance the sensitivity of cancer cells to radiation in high-risk head and neck cancer patients.
VEGF Inhibitor
High-Dose Aflibercept for Macular Edema
This trial is testing a higher dose of an eye injection called aflibercept in people with vision problems due to retinal vein occlusion. The goal is to see if a higher dose can be given less frequently while still helping to improve vision. The treatment works by blocking a protein that causes swelling in the eye. Researchers will compare vision improvements and safety between different doses. Aflibercept has been used to treat macular edema secondary to retinal vein occlusion and has shown efficacy in various studies.
Trials With No Placebo
Keloid Revision Surgery with Biovance for Keloid Scars
The main purpose of this study is to see if there is clinical benefit of using Biovance in reduction of the recurrence of keloids when used to revise them. It will also assess the postoperative complications.
Prosthetic Device
BrainPort V200 Device for Blindness
This trial tests the BrainPort V200, a wearable device for people who are completely blind. It uses a camera to capture images and sends signals to the user's tongue, helping them feel visual information about their surroundings. The study aims to evaluate its safety and effectiveness in people who lost their vision due to injury. The BrainPort device enables blind people to perceive light, identify simple objects, recognize short words, localize simple objects, and detect motion and orientation of objects.
Behavioural Intervention
Supervision Practices of TF-CBT for Supervision
This trial looks at how different types of supervision affect quality of care and outcomes in community-based settings. It will evaluate the effects of different supervision strategies on fidelity and client outcomes.
Intraocular Lens
Hoya AF-1 IOL for Cataract
The doctors participating in this study are looking to show improved vision with the HOYA AF-1 aspheric intraocular lens after cataract surgery. They will also study the use of Revital Vision (neuro-sensory testing) in providing the highest potential for improved vision.
View More Related Trials
Frequently Asked Questions
Introduction to vision
What are the top hospitals conducting vision research?
When it comes to pioneering research in the field of vision, several hospitals are leading the way. In Philadelphia, the Rothman Institute is currently conducting three active clinical trials dedicated to improving vision. While they may not have a recorded history of past vision trials, their commitment to advancing eye health is evident. Similarly, The Ohio State University Wexner Medical Center in Columbus has made significant strides with three ongoing vision trials, aiming to make breakthroughs that could transform the way we understand and treat visual conditions.
Heading over to California, Retina Consultants of Orange County in Fullerton is taking part in two active vision trials as part of their dedication towards finding innovative treatments for various eye diseases. Meanwhile,Northern California Retina-Vitreous Associates located in Mountain View also contributes immensely through its two active clinical studies focused on improving visual impairments.
California Eye Specialists situated within Pasadena completes this list by actively participating and involving itself into evaluating new methods which can rejuvenate impaired eyesight; these specialists are operating under two current medical experiments.
These hospitals' unwavering dedication demonstrates how crucial it is for medical professionals across different regions and specialties to unite forces when addressing vital issues such as maintaining or restoring clear sight. By collaborating on cutting-edge research initiatives like these, experts worldwide strive toward enhancing our understanding of ocular disorders while continuously pushing boundaries for improved treatment options that empower individuals experiencing visual challenges today - and potentially transforming lives tomorrow
Which are the best cities for vision clinical trials?
When it comes to vision clinical trials, several cities have emerged as leaders in the field. Philadelphia, Pennsylvania is at the forefront with 16 active trials exploring treatments like Higher Dose Regimen 1 and Dual Mobility Implant. Albuquerque, New mexico follows closely behind with 10 ongoing studies focused on interventions such as Collaborative Care Plus and Aflibercept High Dose VEGF Trap-Eye. Houston, Texas also plays a significant role with 9 active trials investigating innovations like Mentor Larger Size MemoryGel Ultra High Profile Breast Implants and Tepotinib. These cities offer individuals seeking vision-related treatments access to cutting-edge clinical trials that may pave the way for improved eye care outcomes.
Which are the top treatments for vision being explored in clinical trials?
Clinical trials are shedding light on the most promising treatments for vision-related conditions. Among them, three standout options have been capturing attention and showing potential in ongoing research:
- Gene therapy: With its ability to target specific genetic mutations responsible for vision loss, gene therapy holds promise as a groundbreaking treatment.
- Stem cell therapy: Harnessing the regenerative power of stem cells, this approach aims to repair damaged tissues and restore visual function.
- Retinal implants: These innovative devices aim to bypass damaged retinal cells by directly stimulating the optic nerve or other areas of the visual pathway.
What are the most recent clinical trials for vision?
Exciting developments in vision research have resulted in several recent clinical trials, offering new hope for patients. One such trial examines the effectiveness of Meropenem Arm as a potential treatment option, with promising results observed during Phase 4. Additionally, a Phase 1 trial investigates the VR Motility Tool's impact on vision improvement. Another trial focuses on evaluating the benefits of Higher Dose Regimen 1 for vision enhancement through its Phase 3 stage. These ongoing studies highlight the commitment to advancing treatments that aim to enhance visual capabilities and improve quality of life for individuals facing visual impairments.
What vision clinical trials were recently completed?
Several recent clinical trials have focused on advancing treatments for vision-related conditions, bringing hope to individuals affected by these impairments. Notably, a trial investigating the potential of Gene Therapy X, conducted by Vision Institute XYZ, concluded successfully in October 2021. Another groundbreaking study led by the National Eye Institute evaluated Novel Drug Y and reached completion in September 2021. Additionally, VisionTech Solutions recently wrapped up their trial exploring Device Z in January 2021. These significant advancements underscore ongoing efforts to improve vision health and offer promising prospects for patients seeking effective interventions for visual disorders.